PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

'Sulfur burps' and other GLP-1 things we're learning

28:45Apr 2026

Today’s cheapest GLP-1$39/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.

Our summary

The channel opens with the history of the fat acceptance and Health at Every Size movements and the argument between them and traditional medicine. He says a middle consensus has emerged: fatness is linked to many conditions but is not necessarily their cause, and is an imperfect proxy for a wider web he calls metabolic syndrome. He argues that clinical trial results for these drugs, including benefits in people who did not lose weight, support that view. He also discusses what to call the drug class and settles on "the weight loss drugs."

Published by Adam Ragusea on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

He then interviews David another speaker, a nurse practitioner who writes a blog called The Incretin Space. Another speaker says the most common side effects are nausea, vomiting, constipation and diarrhea, plus heartburn that patients call sulfur burps. He says slow dose titration makes the drugs more tolerable and that nausea has an absolute rate of about 20%, which fades over time. On muscle loss, he says the drugs cause roughly 25 to 35% lean mass loss compared with an expected 25% with crash dieting, and recommends protein and resistance training. He also mentions a slightly higher gallstone risk, which he links to rapid weight loss.

Another speaker says long-term data are limited to trials of about 5 years, but he expects benefits to continue and cites a tirzepatide cardiovascular trial in which weight and A1C stayed controlled with no sign of receptor desensitization. He offers a speculative explanation based on how deeply conserved the hormone family is across species. The pair close by discussing retatrutide, a triple agonist with phase three results due in June, and another speaker's view that obesity rates could fall significantly by 2035. The speaker notes that the interview is not medical advice.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 3:02 The speaker says the drug class has no agreed name, since not all of these drugs act only on GLP-1, and he proposes calling them the weight loss drugs.
  2. 5:40 He argues that benefits seen in trial participants who did not lose weight support the view that fatness is only one part of a wider web of metabolic causes.
  3. 8:44 Another speaker says the main side effects are nausea, vomiting, constipation, diarrhea and heartburn, and that slow titration makes them more manageable.
  4. 12:47 Another speaker says lean mass loss on these drugs runs about 25 to 35% of weight lost, and advises eating protein and doing resistance training.
  5. 17:56 Another speaker cites a roughly 4.5 year tirzepatide trial showing steady weight and A1C control, with no sign of the receptor desensitization seen with some other drug classes.
  6. 23:34 Another speaker says retatrutide acts on GLP-1, GIP and glucagon receptors, with phase three data expected in June and weight loss of 29% at 68 weeks in an earlier phase three trial.

Key moments

Tap one to play from there.

  1. 0:00 The politics of fatness
  2. 3:05 Weight loss drugs arrive
  3. 5:34 The case for vindication
  4. 8:13 Expert talk on side effects
  5. 12:25 Long-term health impacts
  6. 17:25 Mechanisms and evolution
  7. 22:04 Future of obesity treatment

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
retatrutide
Side effects mentioned
nausea, sulfur burps and gallbladder

Questions this video answers

What are the most common side effects of GLP-1 weight loss drugs?

According to nurse practitioner David another speaker, nausea, vomiting, constipation and diarrhea are the big four, with heartburn often added as a fifth. He says the nausea rate is about 20% and tends to drop over time, and that slower titration makes the drugs more tolerable.

What are sulfur burps on GLP-1 drugs?

Another speaker explains that patients use the term for burps linked to the drugs slowing gastric emptying, which he says allows some fermentation in the stomach. He says pineapple and papaya, which contain enzymes, can help manage it.

Do GLP-1 drugs cause muscle loss?

Another speaker says lean mass loss on these drugs is usually about 25 to 35% of the weight lost, compared with an expected 25% from crash dieting. He says the measurement depends on the method used, and he asks patients to get enough protein and do resistance training.

Do GLP-1 drugs stop working over time?

Another speaker points to a roughly 4.5 year, 15,000 patient tirzepatide cardiovascular trial in which most people did not regain weight or need a higher dose. He says he does not see the receptor desensitization seen with some other drugs, and he offers an evolutionary explanation that he labels as speculation.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • GLP-1 vs GLP-2 vs GLP-3: what the names mean, and which ones you can actually buy

    GLP-1 drugs such as semaglutide act on one receptor. "GLP-2" is used online for tirzepatide (Zepbound, Mounjaro), which acts on two, GIP and GLP-1, and "GLP-3" for retatrutide, which adds the glucagon receptor. Neither nickname is the real name: GLP-2 is a separate gut hormone whose drug, Gattex, treats short bowel syndrome. Retatrutide produced 28.3% mean weight loss at 80 weeks in its phase 3 trial but is not FDA-approved; Lilly plans to file in Q1 2027. Tirzepatide is the strongest option you can buy today.

  • What is GLP-1? The hormone, how the drugs work, and every GLP-1 medication on the market

    GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It tells the pancreas to release insulin when blood sugar is high, holds back glucagon, slows how fast the stomach empties, and acts on the parts of the brain that regulate appetite. GLP-1 drugs copy that hormone but last far longer: a week for the injections, a day for the pills. Seven brands are on the US market, from Ozempic and Mounjaro for type 2 diabetes to Wegovy, Zepbound and Foundayo for weight loss.

  • Stopping a GLP-1: what the withdrawal trials found, and what a maintenance dose actually is

    Two trials have measured what happens when you stop. On semaglutide, people who lost 17.3% over 68 weeks regained two-thirds of it in the year after stopping, ending 5.6% below where they started. On tirzepatide, people who lost 20.9% in 36 weeks regained 14% over the next year on placebo while those who continued lost a further 5.5%. Both labels are explicit that these drugs are for maintaining weight reduction long term, which is a different claim from finishing a course. A maintenance dose is simply the dose you stay on; the labels do not define a lower one to step down to at goal.

Next steps

Compounded tirzepatide prices

Find more like it

Side effectsDose changeFood noise and cravingsExercise and strengthHow it worksThe trialsNauseaSulfur burpsGallbladder

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV